Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.60 |
| ▸ | CTSK | P43235 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2481921 | 1.00 | RIPK1 (0.60) | RIPK1CTSKCTSSGPR88MAPT | |
| SCHEMBL127326 | 1.00 | RIPK1 (0.60) | RIPK1CTSKCTSSGPR88MAPT | |
| SCHEMBL2701580 | 0.94 | RIPK1 (0.55) | RIPK1CTSKCTSSGPR88MAPT | |
| SCHEMBL14831426 | 0.91 | CTSK (0.52) | RIPK1CTSKCTSSGPR88ATM | |
| SCHEMBL14831425 | 0.91 | CTSK (0.52) | RIPK1CTSKCTSSGPR88ATM | |
| SCHEMBL21349963 | 0.89 | GPR88 (0.53) | RIPK1CTSKCTSSGPR88 | |
| SCHEMBL56698 | 0.88 | CTSK (0.53) | RIPK1CTSKCTSSMAPTATM | |
| SCHEMBL4353938 | 0.88 | CTSK (0.53) | RIPK1CTSKCTSSMAPTATM | |
| SCHEMBL56596 | 0.88 | CTSK (0.53) | RIPK1CTSKCTSSMAPTATM | |
| SCHEMBL5020954 | 0.88 | CTSK (0.52) | RIPK1CTSKCTSSMAPTCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114641468-B | Process for synthesizing ELAGOLIX sodium salt and intermediate of said process | 工业化学有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | INDUSTRIALE CHIMICA S.R.L. (IT) | 2023-12-12 | — | — | US | claimed |
| US-20220281829-A1 | PROCESS FOR THE SYNTHESIS OF THE SODIUM SALT OF 4-[[(1R)-2-[5-(2-FLUORO-3-METHOXYPHENYL)-3-[[2-FLUORO-6-(TRIFLUOROMETHYL)-PHENYL]METHYL]-3,6-DIHYDRO-4-METHYL-2,6- DIOXO-1(2H)-PYRIMIDINYL]-1- PHENYLETHYL]AMINO]-BUTANOIC ACID (ELAGOLIX SODIUM SALT) AND INTERMEDIATES OF SAID PROCESS | INDUSTRIALE CHIMCA S.R.L. (IT) | 2022-09-08 | — | — | US | claimed |
| CN-114641468-A | Process for the synthesis of the sodium salt of 4- [ [ (1R) -2- [5- (2-fluoro-3-methoxyphenyl) -3- [ [ 2-fluoro-6- (trifluoromethyl) -phenyl ] methyl ] -3, 6-dihydro-4-methyl-2, 6-dioxo-1 (2H) -pyrimidinyl ] -1-phenylethyl ] amino ] -butyric acid (ELAGOLIX sodium salt) and intermediates of said process | 工业化学有限公司 | 2022-06-17 | — | — | CN | claimed |
| US-8338617-B2 | Process for preparing oxazolidine derivatives | DR. REDDY'S LABORATORIES LIMITED (IN) | 2012-12-25 | — | — | US | claimed |
| US-20090131679-A1 | PROCESS FOR PREPARING OXAZOLIDINE DERIVATIVES | DR. REDDY'S LABORATORIES, INC. | 2009-05-21 | — | — | US | claimed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| WO-2025124599-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-06-19 | — | — | WO | disclosed |
| US-20250084042-A1 | Elagolix Sodium Compositions and Processes | ABBVIE INC. | 2025-03-13 | — | — | US | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| CN-114641468-B | Process for synthesizing ELAGOLIX sodium salt and intermediate of said process | 工业化学有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| US-5280027-A | Quinazoline containing compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-18 | — | — | US | disclosed |
| EP-0365045-B1 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1993-12-01 | — | — | EP | disclosed |
| EP-0459730-A2 | Anti-tumour compounds | ZENECA LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
| EP-0161801-B1 | PERHYDROTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANKYO COMPANY LIMITED (JP) | 1990-11-07 | — | — | EP | disclosed |
| EP-0365045-A1 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1990-04-25 | — | — | EP | disclosed |
| US-4699905-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-13 | — | — | US | disclosed |
| EP-0161801-A2 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | RIPK1 728/4885CTSK 1145/4885CTSS 2478/4885 |
| US-20090131679-A1 | PROCESS FOR PREPARING OXAZOLIDINE DERIVATIVES | CYP4X1, CDK19, CDK9 | RIPK1 4683/4885CTSK 4486/4885CTSS 4684/4885 |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | RIPK1 1402/4885CTSK 2620/4885CTSS 1554/4885 |
| US-20250084042-A1 | Elagolix Sodium Compositions and Processes | ELOVL5, ELOC, ELOVL3 | RIPK1 3893/4885CTSK 2635/4885CTSS 3505/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | RIPK1 2996/4885CTSK 2087/4885CTSS 1281/4885 |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | ELP1, BPNT1, EPX | RIPK1 4818/4885CTSK 4856/4885CTSS 4858/4885 |
| US-20220281829-A1 | PROCESS FOR THE SYNTHESIS OF THE SODIUM SALT OF 4-[[(1R)-2-[5-(2-FLUORO-3-METHOXYPHENYL)-3-[[2-FLUORO-6-(TRIFLUOROMETHYL)-PHENYL]METHYL]-3,6-DIHYDRO-4-METHYL-2,6- DIOXO-1(2H)-PYRIMIDINYL]-1- PHENYLETHYL]AMINO]-BUTANOIC ACID (ELAGOLIX SODIUM SALT) AND INTERMEDIATES OF SAID PROCESS | ELP1, BPNT1, EPX | RIPK1 4816/4885CTSK 4854/4885CTSS 4858/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | RIPK1 801/4885CTSK 93/4885CTSS 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.